Automated Liquid Handling Platform

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

FDA OFFICE OF ACQ GRANT SVCS

Contract Value

Not provided

Codes & Classification
Solicitation Number

75F40126Q00423

NAICS

334516 - Analytical Laboratory Instrument Manufacturing

Classification Code

6640

Additional Details
Set Aside

NONE

Place of Performance

Silver Spring, Maryland, UNITED STATES

SourceSAM
The Food and Drug Administration (FDA), operating under the Department of Health and Human Services, has issued a presolicitation notice for the procurement of an Automated Liquid Handling Platform. This opportunity, identified by procurement number 75F40126Q00423, is managed by the FDA Office of Acquisition and Grant Services, located in Silver Spring, Maryland. The notice remains active, with responses now due by 11:00 AM on Wednesday, September 23, 2026, following an amendment that extended the deadline. The primary objective of this procurement is to acquire a newly manufactured, benchtop automated liquid handling platform that will enhance laboratory assay capabilities. The equipment must not be used, refurbished, reconditioned, remanufactured, or previously used for demonstration purposes, ensuring the integrity and reliability of the platform for FDA operations. The scope of work is defined by a set of stringent technical requirements. The platform must be user-friendly, easy to operate and clean, and designed to save both space and energy. It should be capable of rapid automatic pipetting of multiple solutions, including serial dilutions across or down microplate formats. The system must accommodate variable liquid volumes and allow pipetting into single rows, columns, or individual wells, supporting both 96-well and 384-well formats with interchangeable heads. Customizability to laboratory assay needs and programmable operating temperatures are essential, as is compatibility with containment enclosures for handling sterile or hazardous materials. Based on market research, the FDA has determined that only the Agilent Technologies Bravo Automated Liquid Handling Platform meets these minimum requirements. This specific make and model is uniquely suited to the agency’s needs, particularly in its ability to dispense low volumes, fit within a biosafety cabinet, and offer the required precision and flexibility. Other machines in the market do not meet these criteria, especially regarding size and dispensing capabilities. Key deliverables and requirements include: - A benchtop platform that fits and operates within a biosafety cabinet measuring 46 inches wide, 24 inches deep, and 30 inches high, supporting up to 120 lbs without disrupting airflow. - Serial dilution functionality using standard disposable tip heads. - Interchangeable 96-channel and 384-channel pipetting heads with independent tip pickup. - Minimum 15-position deck capacity. - Dispensing range from 0.1 to 200 microliters, with accuracy and precision within 5% deviation. - Configurability for shaking, heating, cooling, and filtration, with the ability to accept these features in the future. - Inclusion of a controller, software for custom protocol generation, and a dedicated computer for machine control. - Compatibility with standard microplates (96-well and 384-well). - Operation under ambient conditions of 5 to 40°C and 10 to 90% relative humidity (non-condensing). - Compliance with all applicable federal, state, and local safety standards. The procurement is classified under NAICS code 334516 (Analytical Laboratory Instrument Manufacturing, 2022 version) and Product Service Code 6640. There are no set-aside requirements for this opportunity, making it open to all qualified vendors. The place of performance is Silver Spring, Maryland, USA. Interested parties should direct inquiries to the primary contact, Reagan Davis, at [email protected] or by phone at 301-796-0910. Further details and updates can be accessed via the official SAM.gov opportunity page: https://sam.gov/opp/80474b69df884b6c9d57ba9b0210fa5e/view. Contractors considering this opportunity should ensure their offerings meet all specified technical and operational requirements, as these elements will remain constant throughout the contract lifecycle. The FDA’s focus on a single-source solution underscores the importance of strict adherence to the outlined specifications and performance standards.